INTRODUCTION
Pancreatic cancer (PDAC) is the fourth leading cause of cancer-related deaths in the United States (1) and has an extremely poor overall five year survival rate of only 4 percent. Most patients present with advanced stage disease and have a median survival of less than one year (2) . Cytotoxic chemotherapy is marginally effective with standard gemcitabine or 5-FU based regimens increasing PDAC median survival by less than 2 months in advanced disease (3) (4) (5) . Published phase III clinical trials of targeted molecular agents in unselected PDAC populations have also not shown robust survival benefits (6) (7) (8) (9) (10) . Ultimately, our evolving understanding of significant genomic diversity in PDAC must be utilized to better inform targeted drug design and delivery.
Recent in-depth exome sequencing showed individual PDAC tumors average more than 60 distinct alterations, the majority of which occur at low frequencies across all tumors.
Only a few high prevalence genomic changes were detected, including expected mutations in KRAS and loss or inactivation of known tumor suppressor genes (e.g.
TP53, SMAD4).
Despite this genomic heterogeneity, all tumors had genetic alterations that were linked to 12 core signaling pathways (11) . Follow-up work comparing patientmatched primary PDAC tumors and subsequent metastases revealed acquisition of further mutations that varied by metastatic site. Strikingly, founder mutations of each metastatic subclone could be traced back to sequenced geographic sub-regions of the primary tumor (12, 13) , providing new insights into the genetic events and timing of PDAC initiation and malignant phenotype. Notably, SMAD4 deletion has been the only genetic alteration from this work that has been linked to patient survival (14) . Author Manuscript Published OnlineFirst on January 18, 2012; DOI: 10.1158/1078-0432.CCR- Others have used gene expression microarray analyses to define molecular signatures associated with PDAC disease progression. Stratford et al. (15) identified a 6 gene signature in primary tumors that was associated with metastatic disease and predicted shorter survival in an independent set of 67 patients. Collisson et al. (16) analyzed primary PDAC from cell lines and a combination of clinical datasets to classify three distinct PDAC molecular subtypes that were able to predict clinical survival, as well as response to therapy in experimental models. While such molecular profiling has provided valuable information, the remarkable genomic diversity of PDAC and the small size of most patient cohorts has clearly hindered the discovery of additionally biologically important molecular changes.
As a means to effectively study diverse genomic alterations in a small patient dataset, we hypothesized that the identification and refinement of prognosis-related genes in PDAC should be improved by increasing the depth of analysis for each tumor using multiple array platforms. The potential for this type of multi-dimensional analysis was shown in a recent prostate cancer study where several pathways of known prognostic significance were validated and new ones were additionally implicated (17) . 
MATERIALS AND METHODS

Patients and samples
All work was performed with UCLA Institutional Review Board approval. Three independent, non-overlapping patient cohorts were used in this study. The initial test cohort of 42 PDAC tumors and 7 non-malignant pancreas samples snap-frozen at the time of surgery were used for microarrays. Of these, only samples with tumor cell content >30% were chosen for final multi-platform analysis (n=25) as determined on representative H&E sections by a practicing gastrointestinal pathologist (DWD). The second patient cohort (n=42) were tumors isolated from FFPE tissue blocks and used as a validation cohort for qPCR. The third patient dataset (n=148) were tumors on a tissue microarray used as an IHC validation cohort. All clinicopathologic and survival information for each patient cohort were extracted from a prospectively maintained UCLA surgical database of pancreatic patients. Disease recurrence was assessed based on biopsy, radiographic evidence or death. The electronic medical record was used to determine associated clinical and pathologic features, as well as disease-free and disease-specific survival. Search of the social security death index (SSDI) was used to determine overall survival. Survival analysis of the TMA cohort was limited to overall survival.
Disease-free, disease-specific and overall survival times were examined for the microarray and qPCR validation cohorts. Survival intervals were calculated from date of surgery to date of confirmed death or last patient contact.
The gene expression was investigated by Affymetrix HGU133 Plus 2 Array on which multiple probe sets might be used to measure expression of a single gene. Therefore, we analyzed the data based on probe set IDs, and used the highest absolute value/score among multiple probe sets for the gene-based interpretation. Details of the array procedure, and normalization and filtering are detailed in the Supplemental Information (SI). In brief, GCRMA was used for normalization, and probe sets having presence calls in less than 30% of samples were eliminated before further analyses.
Cox scores (18) were used to determine the correlation between individual probe setbased expression and disease free survival (DFS) time. Probe sets were then sorted based on the absolute values of their Cox scores. Prediction analysis for microarrays (19) , implemented by Bioconductor pamr package, was then used to determine 1) if expression of the top ranked probe sets could be used to predict the sample outcome and 2) the minimal probe sets to define two prognosis groups with the highest statistical significance.
MicroRNA expression analysis
The Exiqon miRNA arrays (miRCURY LNA™ microRNA Array v.11.0 -hsa, mmu & rno)
were used for measuring genome miRNA expression. Array intensities were adjusted and normalized by variance stabilizing transformation implemented in the Bioconductor vsn packages. The expression profile of each miRNA was represented by the average expression of its multiple spots on the array. Statistical analyses for the association between miRNAs and survival was performed as detailed for gene expression analysis.
Research. 
DNA copy number analysis
Affymetrix SNP 6.0 arrays were used to detect copy number aberrations (CNAs) in tumor samples. CEL files produced by Affymetrix GeneChip Command Console (AGCC) software were imported into Affymetrix GTC 3.0.1, and analyzed using the Copy Number Analysis workflow using HapMap270 as the reference model. Regions with CNAs were then annotated with gene symbols base on the annotation file from the UCSC genome browser (build hg18). Only those genes whose loci had CNA present in at least 20% of the tumors were included for survival analysis in which Cox proportional hazards model was used to determine if the group with CNA at a given locus was at higher risk than the group without CNA.
Integrating multiple dimension data to identify signature genes with multiple levels of evidence
In this meta-analysis, a composite score was generated to quantitatively measure gene prognosis significance based on the multiple array platforms, and is described in detail in the SI. In brief, the composite score was developed based on the assumptions that: besides being correlated to survival, expression of the gene of interest is (1) correlated to its copy number, (2) anti-correlated to its regulating miRNA, and (3) such changes in copy number and miRNA expression are also associated with prognosis. 
Pathway and Gene Ontology Analysis
Survival signature genes were annotated by databases in the public domain: the KEGG and Molecular Signatures Databases (20) . Significant enrichment of pathway/gene set was determined by Fisher exact test.
Validation with Tissue Microarray
The PDAC TMA has been previously detailed (21) and represents a totally separate, non-overlapping cohort of patients. Immunohistochemistry was visualized using Vectastain ABC Elite Kit (Vector Laboratories) following heat-induced antigen-retrieval (0.01M citric acid buffer, pH 6.0) and overnight incubation with primary antibodies (1:100 dilution), including P-SRC (Y418) (Abcam, ab47411) or p85Į (Epitomics, Cat:
1675-1). Three separate 1.0 mm cores for each tumor in the TMA were independently scored by two blinded observers using semi-quantitative histoscores (range 0-300).
Histoscores were the product of staining intensity (0-3) and percentage of tumor cells staining at that intensity (0-100). If any core's histoscore differed by more than 30 points between observers, a revised score was assigned by consensus evaluation.
Median histoscore of both observers was used for analysis.
Quantitative Real Time PCR of Pancreatic Cancer Resection Samples
Statistical Analysis
Survival estimate for each subgroup was generated using the Kaplan-Meier method.
Log-rank test was used to compare Kaplan-Meier curves. Multivariate Cox proportional hazards models were used to test statistical independence and significance of multiple predictors.
RESULTS
Survival based integrated genomic and gene expression analyses
The overall strategy of our survival-based study is outlined in Supplemental Figure 1 .
Integrative multi-platform array analysis was used to simultaneously examine gene expression and regulatory mechanisms from an initial cohort of 25 patients in order to identify and refine genes and pathways with biologic significance. Array analysis was conducted on snap frozen primary patient tissue samples in order to directly link gene expression to genomic and epigenomic changes in the in situ context of primary tumor, and to extract a sufficient source of high quality nucleic acid for simultaneous mRNA, miRNA and SNP microarray analysis. As our goal was to identify genomic alterations and expression changes in neoplastic ductal epithelial cells, we limited our analysis to primary tumor samples where estimated tumor cell content exceeded 30% (median 60%, ranging from 35% to 90%). This cutoff was chosen after initial unsupervised clustering of microarrays comparing mRNA expression from normal pancreas, chronic pancreatitis and pancreas tumor samples showed tumors with low tumor cell content (< 30%) more frequently clustered with normal and chronic pancreatitis controls (data not shown), consistent with previous work showing a large stromal content can confound array readouts in PDAC (22) . Specific molecular alterations identified through this integrated genomic analysis were then independently validated in separate, nonoverlapping patient cohorts by immunohistochemistry (n=148) or qPCR (n=42), whose clinicopathologic characteristics and survival outcomes largely overlap (Supplemental Table 1 Table 1 provides the clinical and histopathologic parameters for the 25 patients. All patients had early stage PDAC and received adjuvant chemotherapy after surgery. At the time of analysis, 16 patients had recurrent disease with a median disease-free survival time (DFS) of 13.3 months, and ten of them had died of disease with a median disease-specific survival (DSS) of 20.6 months. Given the number of deaths and relatively short follow-up time (median 12.4 months for survivors) in our cohort, DFS was chosen as the outcome measure for our analysis. DFS is considered an accurate metric of survival outcome, as most patients with recurrent PDAC will succumb to disease. The clinicopathologic characteristics and survival outcomes of our cohort was similar to other published large cohorts of early stage PDAC (23) .
Copy number variations and mRNA and miRNA expression alterations as predictors of PDAC survival
We first individually analyzed mRNA expression, miRNA expression and DNA copy number to determine DFS-associated changes in each microarray platform. For mRNA analysis, we used a non-grouping-based approach addressing survival as a continuous variable. The advantage of this approach over a grouping-based approach is that it does not set an arbitrary survival time threshold for dichotomization and thus better accounts for tumors with a continuum of clinical behavior (18) . A semi-supervised clustering methodology was used whereby a Cox score was first generated for each gene based on a direct correlation between its expression and DFS. Signature genes were then prioritized and selected based on the absolute value of their Cox scores.
Using this method, the most accurate gene set is selected from a series of prediction analyses whereby different cut-off points are iterated to establish an optimal panel of genes accurately separating different prognosis subgroups. The top 500 scored probe sets (Supplemental Table 2 ) from this approach included 186 up-and 314 downregulated transcripts able to segregate two highly significant and distinct prognosis groups (median DFS = 7.7 vs. 25.3 months; log-rank test p=0.000038; Figure 1A ). The non-grouping approach was also utilized for separate miRNA microarray analysis, which yielded a panel of 31 miRNAs (1.8% of the total) able to robustly segregate two prognosis groups (median DFS = 9 vs. >36 months; p=0.00047; Figure 1B and Supplemental Table 3 ).
For survival-based analysis of DNA copy number aberrations (CNA), CNAs for each tumor were determined by comparing Affymetrix SNP microarray to the human hapmap reference model using Affymetric GTC software. CNAs were then mapped to specific gene loci using UCSC genome build hg18. Because of the size of our cohort, we focused on CNAs occurring at higher frequency ( 20% of the samples) and relaxed the cut-off to include Cox values approaching significance (p-value < 0.2). High frequency CNAs were clustered on chromosomes 1, 7, 8, and 20 for amplifications and chromosomes 6, 9, 17, and 18 for deletions ( Figure 1C, upper panel) . However, among them, the prognosis significant CNAs ( Figure 1C , bottom panel) were located on specific loci, including amplifications on chromosomes 7, 11, 19, 20, and 22, and deletions on chromosomes 6 and 9. We identified CNAs associated with a total of 68 genes that optimally segregated patients into two statistically significant prognosis groups (median DFS = 9.7 vs. 25.0 months, log rank test p=0.0063, Figure 1D and Supplemental Table 4 ).
Integrated Molecular Analyses Further Refines Genes of Prognostic Importance in PDAC
Although our initial analysis demonstrated a large number and variety of molecular alterations correlated with DFS in PDAC, it was less clear which alterations mechanistically link to the malignant phenotype or represent clinically useful biomarkers. While analysis of larger patient datasets can help address these questions, the cost and availability of large PDAC patient datasets are limiting. As an alternative, we hypothesized that relevant associations could be strengthened and refined in our cohort through an integrated assessment of gene expression in conjunction with concordant changes in genetic and epigenetic regulation.
We merged results from all three microarray platforms to generate a single composite score that integrates CNA and levels of mRNA and miRNA expression (see Supplemental Figure 1 and Supplemental Information). To associate genes with miRNAs, a list of 2.1 million potential miRNA-mRNA seed-match pairs were first generated from data in the public domain, including experimental evidence in TarBase® (24) and predictive sequence analysis using TargetScanS® (25) and miRbase® (26) .
Next, each component in the composite score was given a weight based on its ability to independently identify two prognosis groups. Individually, mRNA expression was the most robust predictor of DFS in our analysis, followed by miRNA expression and CNA 
changes, as determined by the log rank p-values generated from each platform ( Figure   1 ). The log 10 transformations of these p-values were used to weight each platform's contribution to survival in the final composite score calculation for each gene, whereby a gene's mRNA expression was weighted most heavily, followed by its linked miRNA alterations and finally CNA (see Supplemental Methods). The composite score also took into account whether there was concordance between CNA-gene expression (e.g. 
adhesion and insulin signaling (Supplemental Table 6 ). Therefore, our data offers survival-based correlations to support an existing literature that links these pathways to pancreatic tumorigenesis (27) (28) (29) (30) (31) . Our data also offers potential insights into novel mechanisms regulating these pathways and their relationship to clinical disease progression. Several survival-correlated genes in our integrated composite signature uniformly link poor prognosis to changes that will result in upregulation of PI3K/AKT/mTOR and SRC signaling (Figure 3 ). For instance, the expression of EGFR, a potential activator of both AKT and SRC signaling, was associated with worse prognosis in our analysis (Cox score +2.77), while that of CBL, a ubiquitin ligase able to negatively impact EGFR (32) or SRC(33) expression, correlated with improved survival in our analysis (Cox score -2.4). PIK3R1, which encodes the class Ia PI3K regulatory subunit p85Į that antagonizes PI3K/AKT signaling, also correlated with improved survival (Cox score -2.5). Prognosis-linked changes in gene expression were more frequently correlated with prognosis-significant miRNA changes, implicating miRNAs as a critical factor in the malignant phenotype of PDAC (see Supplemental Table 3 ). For example, our data suggested prognosis-linked expression PIK3R1/p85Į mRNA could be mediated by miRNA 519d, which is 1) broadly conserved among vertebrates, 2) predicted to bind to the 3' untranslated region of PI3KR1, 3) inversely correlated with PIK3R1 expression in our analysis, and 4) an independent predictor shorter DFS (miRNA expression Cox score +2.42).
Highlighting the value of the integrated composite score over gene expression alone, SRC was not identified on independent mRNA array analysis, as it showed only a weak non-significant trend towards worse prognosis (Cox expression score +1.22). However, SRC was subsequently captured as a high ranking gene (#21) in our integrated composite signature when its prognosis-significant (Cox Hazard Ratio = 4.1, p-value = 0.016) genomic amplification was considered with mRNA expression. Prognosisrelated dysregulation of SRC was also inferred from our subsequent pathway analysis.
SRC activation can occur through integrin-FAK-dependent (34, 35) or FAK-independent (36) mechanisms facilitated by PTPRA, which was associated with worse prognosis in our integrated composite signature (Cox score +2.24). ARFGAP1, which also correlated with worse prognosis in our analysis (Cox Score +1.62), has been shown to potentate SRC downstream signaling via its regulation of the actin cytoskeleton and, leading to enhanced cell motility (37) . Interestingly, SRC, PTPRA, and ARFGAP1 are all located on chromosome 20. While SRC is regulated by amplification, both PTPRA and ARFGAP1 can be regulated by amplification and by miR541, which was inversely correlated with DFS (Cox score -3.12), again revealing the strength of our integrated approach.
Validation of Molecular Signatures
To validate the predictive value of genes in our integrated composite signature, we chose to focus on SRC and the PI3K/AKT signaling given that 1) they were populated with centrally located prognosis significant genes, 2) they are known to be dysregulated in human PDAC (35, 38) (Table 1 and Supplemental Table 1 ). IHC staining for each tumor was determined semi-quantitatively by histoscore, with a broad staining distribution seen for each antibody across the TMA ( Figure 4B&C ). For each IHC marker, patients were dichotomized on a histoscore cutoff value of 150, chosen to identify groups sufficiently populated for statistical power analysis and that minimized the chance of assigning patients with small differences to opposite groups. Neither P-SRC nor p85Į expression was associated with various clinicopathologic factors, with the exception that low We finally sought to validate the finding that CBL was linked to prognosis in our integrated composite signature (Figure 3 ). In the absence of a reliable IHC assay, we pursued survival-based quantitative PCR analysis of CBL normalized to ACTB in a separate cohort of 42 PDAC samples; these patients had a similar DSS with the array and TMA cohorts (25.4 vs. 19.8 vs. 24.2 months respectively), given the differences in follow-up times (Table 1 and Supplemental Table 1 ). Patients were again dichotomized into groups with low versus high CBL expression, the latter of which significantly correlated with better survival (median survival 44.3 vs. 20.6, p = 0.03, Figure 5E ).
DISCUSSION
The large number and wide range of genetic alterations that characterize pancreatic cancer present both significant challenges and opportunities for improving our understanding and treatment of this highly aggressive and lethal malignancy. Seminal large scale genomic sequencing studies of PDAC offer a tantalizing spatial and temporal picture of the genomic alterations occurring in both primary tumors and metastatic lesions, but must also now be examined in greater detail to establish their association with the malignant phenotype of PDAC (11) (12) (13) . We have adopted an integrative approach to identify and prioritize genes of potential importance in PDAC.
Our survival based approach involved multi-dimensional analysis of gene expression, and genomic and epigenomic regulatory mechanisms. This novel strategy allowed us to identify and refine prognosis significant genes, some of which would not have been identified based on expression alone (e.g. SRC). We also highlight several 
observations based on our integrated composite gene signature and subsequent pathway and gene-ontology based analysis.
1. Many of the pathways enriched for survival-correlated genes in our analysis have already been implicated in pancreatic cancer including ERBB, focal adhesion, insulin signaling and MAPK pathways (Supplemental Table 6 ). Several of these pathways are linked by EGFR, which itself appears in our integrated composite signature. This is not unexpected as it has been shown that EGFR is overexpressed and associated with disease progression and poor prognosis in PDAC (30, 31) . Apart from EGFR, our integrated composite signature contained several additional prognosis-associated genes linked to both SRC signaling and the PI3K/AKT pathway. These included SRC, PIK3R1/p85Į and CBL, important regulatory components that we further linked to PDAC survival in separate validation cohorts by either protein or gene expression.
The PI3K/AKT pathway can promote both PDAC initiation and invasive cancer progression. AKT activity is enhanced in up to 60% of PDAC tissues and cell lines (38) .
More recently, we showed PI3K pathway activation is critical for the onset and Instead, our data offers potential alternative mechanisms for PI3K/AKT/mTOR dysregulation in PDAC. These include increased expression of the upstream receptor tyrosine kinase EGFR and downregulation of the p110 regulatory subunit p85α encoded by PI3KR1, possibly through silencing mediated by prognostically-linked miR519d. As validation of these observations, we showed p85Į protein expression to be inversely correlated with overall survival in our large PDAC TMA cohort. Likewise, either p85Į or PTEN loss was found to further correlate with increased P-AKT and P-S6 status as measured in a small cohort of PDAC tumors by IHC (Supplemental Figure 3) .
Our findings are consistent with previous studies reporting higher levels of SRC expression are associated with worse DFS in PDAC (35, 46) . SRC is the signature member of a family of non-receptor tyrosine kinases able to mediate diverse effects on cellular proliferation, differentiation, survival, motility, and angiogenesis (47) . It is activated through multiple mechanisms, including via integrins and membrane-bound receptor tyrosine kinases (e.g. EGFR) (36) . SRC overexpression and its activation (as detected by Y419 phosphorylation) is seen in most PDACs (48) (35) . Likewise, mice with conditional Kras activation and deletion of the SRC inhibitory kinase Csk develop invasive PDAC more rapidly and at higher prevalence than those with intact Csk (49). 
